drugset / Trial / NCT02311101
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study aims to establish the safety and toxicity of a combined intravesical mitomycin C with BCG for patients with bladder cancer.
Timeline
- Start
- 2012-03
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCG | Unknown | — | — |
| Subject | Mitomycin C | Other / unclassified | 10 mg | Intravenous |
| Subject | Mitomycin C | Other / unclassified | 20 mg | Intravenous |
| Subject | Mitomycin C | Other / unclassified | 40 mg | Intravenous |